Literature DB >> 16679292

Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta.

Cullen M Taniguchi1, Tatsuya Kondo, Mini Sajan, Ji Luo, Roderick Bronson, Tomoichiro Asano, Robert Farese, Lewis C Cantley, C Ronald Kahn.   

Abstract

Although the class I(A) phosphoinositide 3-kinase (PI3K) pathway is central to the metabolic actions of insulin, its mechanism of action is not well understood. To identify the role of the PI3K pathway in insulin regulation of hepatic function, we ablated the expression of both major regulatory subunits of PI3K by crossing mice lacking Pik3r1 in liver with Pik3r2 null mice, creating liver-specific double knockout mice (L-p85DKO). L-p85DKO mice failed to activate PI3K or generate PIP(3) upon insulin stimulation or activate its two major effectors, Akt and PKClambda/xi. Decreased Akt activation resulted in increased gluconeogenic gene expression, impaired glucose tolerance, and hyperinsulinemia, while the defective activation of PKClambda/xi by insulin was associated with hypolipidemia and decreased transcription of SREBP-1c. These data indicate that the PI3K pathway is critical for insulin's actions in the liver in vivo, and that differential regulation by Akt and PKClambda/xi differentially defines specific actions of insulin and PI3K on hepatic glucose and lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679292     DOI: 10.1016/j.cmet.2006.04.005

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  117 in total

1.  Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation.

Authors:  Mini P Sajan; Robert A Ivey; Mackenzie C Lee; Robert V Farese
Journal:  J Lipid Res       Date:  2014-11-13       Impact factor: 5.922

2.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 3.  Atypical protein kinase C in cardiometabolic abnormalities.

Authors:  Robert V Farese; Mini P Sajan
Journal:  Curr Opin Lipidol       Date:  2012-06       Impact factor: 4.776

4.  Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c.

Authors:  Min Wan; Karla F Leavens; Danish Saleh; Rachael M Easton; David A Guertin; Timothy R Peterson; Klaus H Kaestner; David M Sabatini; Morris J Birnbaum
Journal:  Cell Metab       Date:  2011-10-05       Impact factor: 27.287

5.  BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans.

Authors:  Mini P Sajan; Robert A Ivey; Robert V Farese
Journal:  Metabolism       Date:  2015-08-24       Impact factor: 8.694

6.  Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.

Authors:  Cullen M Taniguchi; Thien T Tran; Tatsuya Kondo; Ji Luo; Kohjiro Ueki; Lewis C Cantley; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

7.  Exposure to p,p'-dichlorodiphenyldichloroethylene (DDE) induces fasting hyperglycemia without insulin resistance in male C57BL/6H mice.

Authors:  George E Howell; Edward Meek; Jessica Kilic; Mariel Mohns; Charlee Mulligan; Janice E Chambers
Journal:  Toxicology       Date:  2014-02-26       Impact factor: 4.221

8.  Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis.

Authors:  Sushant Bhatnagar; Holly A Damron; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

Review 9.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

10.  Low-Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms.

Authors:  Stanley Andrisse; Shameka Childress; Yaping Ma; Katelyn Billings; Yi Chen; Ping Xue; Ashley Stewart; Momodou L Sonko; Andrew Wolfe; Sheng Wu
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.